solabegron

Known as: (R)-3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid, 3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic Acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
β3-Adrenoceptor agonists were originally considered as a promising drug class for the treatment of obesity and/or type 2 diabetes… Expand
Is this relevant?
Review
2015
Review
2015
INTRODUCTION Antimuscarinic drugs form the mainstay of medical treatment for Overactive bladder Syndrome (OAB). With a proven… Expand
Is this relevant?
2012
2012
BACKGROUND β-Adrenoceptor agonists are effective in animal models of bladder dysfunction, and the human bladder primarily… Expand
  • figure 1
  • figure 2
  • table 2
  • table 1
  • figure 3
Is this relevant?
2012
2012
The interesting paper published in this edition of European Urology represents the first full publication of phase 2 data with a… Expand
Is this relevant?
2010
2010
BACKGROUND & AIMS beta3 Adrenoceptor (beta3-AR) is expressed on adipocytes and enteric neurons. GW427353 is a human selective… Expand
  • figure 5
  • figure 4
Is this relevant?
2009
2009
PURPOSE We investigated the presence of functional Beta1, Beta2 and Beta3-adrenoceptor in urothelium and detrusor muscle of human… Expand
Is this relevant?
2008
2008
beta(3)-Adrenoceptors(beta(3)-AR) are expressed by cholinergic myenteric neurons and beta(3)-AR agonists are effective in… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2008
2008
April B. M. Grudell, Michael Camilleri, Kim L. Jensen, Amy E. Foxx-Orenstein, Duane D. Burton, Michael D. Ryks, Kari L. Baxter… Expand
  • table 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2007
2007
Functional studies have demonstrated that adrenoceptor agonist-evoked relaxation is mediated primarily by beta3-adrenergic… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2004
2004
agonists as viable antiobestic or antidiabetic agents with improved potency are pursued. Most of β3-AR agonists tested in… Expand
  • figure 1
  • table 1
Is this relevant?